Lundbeck is currently evaluating the compound in a Phase 1b clinical trial, focusing on its safety and pharmacodynamic profile. The drug acts as an agonist for the orexin 2 receptor (OX2R), a key component in the brain’s wake-promoting signaling pathway. In patients with narcolepsy, the loss or dysfunction of this signaling leads to chronic sleep-wake instability, often manifesting as excessive daytime sleepiness, sleep attacks, and in some cases, cataplexy.

Johan Luthman, Executive Vice President of R&D at Lundbeck, stated that the designation validates the potential of targeting orexin biology to restore normal sleep patterns. While current therapies help manage individual symptoms, many patients continue to face significant challenges in their daily functioning and quality of life. The FDA’s decision is intended to expedite the development and review process for medicines addressing these serious unmet medical needs. Lu AH69593 remains an investigational compound with its efficacy and safety yet to be established in broader clinical settings.